Solide Tumoren - Verdauungstrakt - Dünndarmkarzinom -

Weiterführende Informationen

Leitlinien

Wegen der Seltenheit sind keine Leitlinien definiert.

Literatur

1. Zaanan A et al: Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 2010; 21: 1786–93
2. Zaanan A et al: Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer. 2011; 117: 1422–8
3. Bilimoria KY et al: Small bowel cancer in the United States: Changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249: 63–71
4. Fishman PN et al: Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol 2006; 29: 225–31
5. Kretzschmar A et al: Small bowel adenocarcinoma: cytotoxic chemotherapy in palliative indication is more effective than commonly thought – retrospective analysis of 32 cases. Onkologie 2005; 28 (suppl 3): 734
6. Laukoetter MG et al: Intestinal cancer risk in crohn’s disease: a meta-analysis J Gastrointest Surg. 2011; 15: 576–83
7. Lesquereux-Martínez L et al: Adenocarcinoma arising in Meckel's diverticulum: a case report and literature review. Gastroenterol Hepatol. 2011; 34: 137–40
8. Overman MJ et al: Final response data of a phase II study of capecitabine and oxaliplatin (capox) in advanced adenocarcinoma of the small bowel or ampulla of vater. J Clin Oncol 2008; 26 (15S): #4538